Kazakhstan: CIS region’s most consistent performer

Across the CIS region, pharmaceuticals have long served as the quiet shock absorber of healthcare systems and industrial development, an industry that has continued to expand even as its surrounding environment has shifted through macroeconomic cycles, geopolitical realignments, and regulatory resets. Russia remains the anchor, projected to exceed US$ 25 billion in pharmaceutical sales by 2025, according to early Frost & Sullivan estimates. Kazakhstan, though far smaller at just over US$ 2.5 billion, has emerged as the region’s most consistent performer.

Over the last three years, Kazakhstan has delivered an estimated 12%–15% CAGR, outpacing several CIS peers and defying the region’s reputation for volatility. While growth is expected to moderate to 8%–10% annually through 2027–2028 as procurement stabilizes and price capping tightens, the country remains one of the few markets in the bloc where predictable expansion feels almost structural. In a geography often associated with sharp policy swings or currency corrections, this level of steadiness stands out, and invites a deeper question.

Why does Kazakhstan diverge from CIS norm?
Part of the answer lies in the familiar regional forces: an ageing population, a rising middle class, an increased chronic disease burden, and sustained public investment in healthcare security. Yet these drivers alone do not explain Kazakhstan’s trajectory. What differentiates the country is its calibrated policy approach, reform without shock, localization without coercion, and market openness without the instability that sometimes accompanies rapid integration.

This balance has enabled Kazakhstan to evolve from a domestic-demand market into an emerging regional node. Its alignment with the Eurasian Economic Union (EAEU) has harmonized technical standards, eased cross-border registration, and positioned Kazakhstan as a strategic entry point into a 180-million-population corridor across Central Asia and the wider EAEU sphere. Increasingly, the focus is shifting toward positioning Kazakhstan not as an isolated opportunity, but as a pharma hub for the region.

India’s expanding footprint: A trade corridor turning strategic
For India, this evolving landscape has opened an important commercial bridge. With Kazakhstan importing nearly 75%–80% of its pharmaceutical requirements, Indian manufacturers have steadily strengthened their presence. According to UN Comtrade data analyzed by Frost & Sullivan, India’s exports to Kazakhstan rose from US$ 51 million in 2019 to almost US$ 89 million in 2024, a >9% CAGR, achieved during a period when several CIS markets experienced contraction or stagnation.

The depth of India’s portfolio is equally notable. Cardiovascular therapies, anti-diabetics, anti-infectives, oncology lines, dermatology and respiratory treatments, and an expanding basket of critical-care injectables collectively reflect a broad therapeutic alignment with Kazakhstan’s disease profile. Yet the market is no longer defined solely by import opportunity. It is shifting toward a more controlled, capability-driven structure where localization is rising, though in a measured, and predictable way.

Localization without disruption: Kazakhstan’s gradual industrial turn
Kazakhstan has set an ambitious objective: expanding domestic pharmaceutical production from roughly 15 per cent today to 50 per cent by 2029. But the approach matters. Rather than pursuing rapid import substitution, common in some emerging markets, the country is adopting a phased, incentive-driven model that rewards partnership instead of displacing existing suppliers.

Reforms already shaping the competitive landscape include:

Accelerated drug registration pathways, with timelines shortened to around 100 working days.

Investment incentives tied to full-cycle production, encouraging technology transfer, local value addition, and sustained partnership.

Yet this success story introduces the need for new pivots. Companies relying purely on import-led models risk gradual marginalization in procurement as domestic-content preferences expand. Conversely, firms adopting blended strategies, local assembly, fill-finish, packaging partnerships, or shared manufacturing, stand to secure privileged access in the next decade, particularly in the very large public sector (almost >40% according to some industry KOLs).

For Indian stakeholders, the implication is clear: Kazakhstan is evolving from a consumption market into a co-production, and co-development opportunity. Indian firms can operate as both suppliers and industrial partners, strengthening Kazakhstan’s manufacturing base while gaining long-term visibility across the region.

Why Kazakhstan matters now: Stability in a time of global flux
Global pharmaceutical markets are entering a period defined by pricing pressures, volatile trade policy, and higher compliance barriers. As the US and EU tighten norms around quality, traceability, and environmental standards, and as geopolitical challenges reshape trade flows, Indian exporters increasingly seek diversified geographies that offer stability without compressing margins.

Kazakhstan offers precisely this equilibrium. Transparent procurement mechanisms, relatively moderate currency fluctuations, and predictable regulatory transitions collectively create an operating environment that rewards consistency and scale.

Adding to this is an evolving demand profile. While generics and primary-care therapies still dominate local manufacturing investments, the clinical landscape is shifting toward high-potency products, oncology agents, biosimilars for autoimmune conditions, and complex hospital injectables, creating a widening capability gap that aligns closely with India’s emerging strengths.

Capability gap: Where India’s expertise meets Kazakhstan’s next-stage needs
Despite strong policy momentum, Kazakhstan’s domestic pharma industry remains constrained in upstream capacities, particularly complex APIs and intermediates. These capabilities along with biologics, peptides, hormones, fermentation-based APIs, and advanced formulations, are precisely where Indian investment has accelerated over the past five years.

What emerges when a market’s complexity rises faster than its manufacturing base, and when a trading partner can supply both scale and technological depth? A mutually reinforcing ecosystem. Kazakhstan requires capability upgrading; India brings cost-efficient science and industrial experience; and the EAEU framework amplifies market reach.

This is why the narrative today feels less like a traditional export story and more like the early architecture of a long-term industrial partnership.

Procurement reform: A new premium on partnership
Kazakhstan’s procurement ecosystem has undergone meaningful modernization. Transparency has improved, evaluation criteria have sharpened, and the system increasingly favors manufacturers committed to local presence or capability transfer. In essence, the procurement model now rewards those who invest in the system rather than those who simply sell into it.

Indian companies have historically excelled in relationship-driven, long-cycle environments, across Africa, Southeast Asia, and Latin America, blending R&D collaboration, quality assurance, and sustained affordability. Kazakhstan’s evolving model is a natural extension of this playbook.

The most visible proof point is MSN Laboratories’ US$ 60 million collaboration with Medservice Plus to establish a full-cycle API-to-FDF facility in Almaty. This is more than a single project; it is a signal of strategic intent. It reflects a broader shift in how Indian companies engage with the CIS market: not merely as exporters, but as co-investors in regional capability.

The question now is not whether Kazakhstan offers opportunity, but how Indian firms choose to shape it.

A converging future: From trade to co-creation
Kazakhstan’s pharmaceutical ascent is unfolding at a moment when India is rethinking its global positioning. As India diversifies export destinations, deepens technological competitiveness, and strengthens backward integration, it is actively seeking markets where regulatory predictability and industrial partnership converge. Kazakhstan’s commitment to phased localization, its openness to investment, and its alignment with the broader EAEU market create a platform where Indian firms can secure commercial longevity while contributing to regional health security.

In the years ahead, the CIS region is likely to undergo continued policy recalibration and supply-chain diversification. Yet Kazakhstan’s steady trajectory, and its receptiveness to structured, long-term collaboration, positions it as one of the most strategically valuable markets for Indian pharmaceutical players seeking stability, depth, and expanded regional influence.